Article Versions Notes

Katona G, Balogh GT, Dargó G, Gáspár R, Márki Á, Ducza E, Sztojkov-Ivanov A, Tömösi F, Kecskeméti G, Janáky T, et al. Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach. Pharmaceutics. 2020; 12(2):97. https://doi.org/10.3390/pharmaceutics12020097

Katona, Gábor, György Tibor Balogh, Gergő Dargó, Róbert Gáspár, Árpád Márki, Eszter Ducza, Anita Sztojkov-Ivanov, Ferenc Tömösi, Gábor Kecskeméti, Tamás Janáky, and et al. 2020. "Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach" Pharmaceutics 12, no. 2: 97. https://doi.org/10.3390/pharmaceutics12020097

Katona, G., Balogh, G. T., Dargó, G., Gáspár, R., Márki, Á., Ducza, E., Sztojkov-Ivanov, A., Tömösi, F., Kecskeméti, G., Janáky, T., Kiss, T., Ambrus, R., Pallagi, E., Szabó-Révész, P., & Csóka, I. (2020). Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach. Pharmaceutics, 12(2), 97. https://doi.org/10.3390/pharmaceutics12020097